Skip to content

Disc Medicine IRON Change in Accrued Liabilities

Change in Accrued Liabilities at other companies

Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
-$10.79M+8.7%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
-$19.17M+26.6%
Beam Therapeutics logo
Beam TherapeuticsBEAM
-$16.26M+11.9%
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
-$20.9M-119%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-$37.48M-93.5%

Other financials

Income statement

See full
Operating income-$69.5M-74.0%
Net income-$63.5M-86.3%
EPS (diluted)-$1.65-61.8%

Balance sheet

See full
Cash & equivalents$88.9M-27.5%
Total debt$31.1M+1.4%
Total equity$688.4M+4.3%
Total assets$750.2M+5.8%

Cash flow

See full
Operating cash flow-$62.2M-50.4%
CapEx--100%
Free cash flow-$62.2M-47.4%

Valuation

See full
Market cap$2.69B+42.2%
Enterprise value$2.63B+46.7%

Returns & leverage

See full
Return on equity-35.8%+41.3pp
Debt / equity0.0×
Current ratio24×-13.6×

Where this comes from

Reported directly by Disc Medicine in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherAccruedLiabilities.

The official record: Disc Medicine’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Disc Medicine's change in accrued liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Disc Medicine's change in accrued liabilities?
Disc Medicine (IRON) reported change in accrued liabilities of -$8.73M in Q1 2026.
How has Disc Medicine's change in accrued liabilities changed year-over-year?
Disc Medicine's change in accrued liabilities decreased by 136.8% year-over-year, from -$3.69M to -$8.73M.
What is the long-term trend for Disc Medicine's change in accrued liabilities?
Over 2 years (2022 to 2025), Disc Medicine's change in accrued liabilities has grown at a 114.1% compound annual growth rate (CAGR), from $1.5M to $6.88M.
What does change in accrued liabilities mean?
Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.